|
1
|
Structure based drug design: development of potent and selective factor IXa (FIXa) inhibitors.
|
J Med Chem
|
2010
|
2.28
|
|
2
|
Essential myosin light chain as a target for caspase-3 in failing myocardium.
|
Proc Natl Acad Sci U S A
|
2002
|
1.21
|
|
3
|
Direct detection of antibody concentration and affinity in human serum using microscale thermophoresis.
|
Anal Chem
|
2012
|
1.01
|
|
4
|
Effect of the oxLDL binding protein Fc-CD68 on plaque extension and vulnerability in atherosclerosis.
|
Circ Res
|
2011
|
1.01
|
|
5
|
Administration of the cyclic peptide COR-1 in humans (phase I study): ex vivo measurements of anti-β1-adrenergic receptor antibody neutralization and of immune parameters.
|
Eur J Heart Fail
|
2012
|
0.92
|
|
6
|
The GPVI-Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke.
|
PLoS One
|
2013
|
0.89
|
|
7
|
The GPVI-Fc fusion protein Revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times.
|
PLoS One
|
2013
|
0.81
|
|
8
|
Overexpression of ABCG1 protein attenuates arteriosclerosis and endothelial dysfunction in atherosclerotic rabbits.
|
Heart Int
|
2012
|
0.75
|